For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
On November 28, 2019 the Pharmaceutical Inspection Co-Operation Scheme (PIC/S) published a draft Recommendation for Participating Authorities, providing practical guidance for GMP inspectors, on how to evaluate the effectiveness of a pharmaceutical quality system (PQS) in relation to risk-based change management.(1)
The PIC/S GMP Guide requires companies to have an effective PQS and apply quality risk management (QRM) principles to change control activities.
Chapter 1 states:
· Principle: …there must be ‘a comprehensively designed and correctly implemented Pharmaceutical Quality System incorporating Good Manufacturing Practice and Quality Risk Management. It should be fully documented and its effectiveness monitored’.
· 1.3 ...’the effectiveness of the system is normally demonstrated at the site level’.
· 1.5 ‘Senior management has the ultimate responsibility to ensure an effective Pharmaceutical Quality System is in place...’
· 1.4 (xii) Arrangements [should be] in place ‘for the prospective evaluation of planned changes and their approval prior to implementation…’
Annex 15 states:
· 11.1. ‘The control of change is an important part of knowledge management and should be handled within the pharmaceutical quality system.’
· 11.4. ‘Quality risk management should be used to evaluate planned changes… and to plan for any necessary process validation, verification or requalification efforts.’
· 11.7. ‘…an evaluation of the effectiveness of change should be carried out…’
The recommendation was prepared by the PIC/S Expert Circle on QRM and does not create any new GMP requirements or expectations. It simply provides inspectors with a tool to support an evaluation of PQS effectiveness in relation to risk-based change management. It has been designed to help inspectors increase their understanding of what risk-based change management means at a practical level, and then give a framework to help see how effective implementation might be demonstrated by pharmaceutical companies. The tool provides a checklist approach focusing on:
· Change proposals – Determination of when a change is needed
· Change risk assessments
· Change Planning and implementation
· Change review and effectiveness
The recommendation is currently a draft that is being applied on a 6-month trial basis, with an expectation that formal adoption will subsequently occur on a revised version following comments on use of the tool by PIC/S participating authorities.
Of more significance than the use of the tool by inspectors over the coming months, is that this move starts to see a shift, albeit a small one, towards greater risk-based regulatory oversight as envisaged in ICH Q10 (Pharmaceutical Quality System) and Q12 (Lifecycle Management). (2)
EU-CTR: Preparing for trial transition
Nov 30, 2023
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
8 things you need to know about eCTDs in China
Jul 1, 2022
RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry
Jun 16, 2022
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
On-demand webinar: An expert guide to EU-CTR
Mar 10, 2022
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022
Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)
Jan 26, 2022
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Biosimilar Development: Are therapeutic clinical trials needed?
Nov 16, 2021
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021